Movement Alert|SELLAS Life Sciences Group Inc. Overnight Decline 9.14%, Public Offering Plan Pressures Shares

Market Focus11-18 09:03

On November 18, SELLAS Life Sciences Group Inc. fell 9.14% Overnight, trading at $17.39 per share, with turnover of $19,500.

The move followed the company’s launch of a $150.0 million underwritten public offering of common stock, with underwriters receiving a 30-day option to purchase up to an additional $22.5 million of shares.

The financing announcement came immediately after the stock’s sharp rally driven by positive Phase 3 REGAL data for galinpepimut-S in acute myeloid leukemia. The company reported the study met its primary endpoint, with median overall survival of 24 months versus 14.7 months for the control arm and a 41% reduction in risk of death, while saying it plans to discuss an accelerated regulatory filing strategy with the FDA. The equity raise suggests SELLAS Life Sciences Group Inc. is moving quickly to fund regulatory and commercialization steps, but the expected share issuance weighed on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment